
arGEN-X appoints Evotec chief executive
pharmafile | April 14, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Evotec, arGEN-X, lanthaler
Belgium-based clinical stage human therapeutic antibody firm arGEN-X has appointed Dr Werner Lanthaler to its supervisory board.
Lanthaler is currently chief executive of Evotec as has been since March 2009. Prior to that he spent nine years as chief financial officer at Intercell AG between 2000 and 2009.
From 1998 to 2000 Lanthaler served as director of the Federation of Austrian Industry, and from 1995 to 1998 as senior management consultant for the consulting firm McKinsey & Company.
Peter Verhaeghe, chairman of the arGEN-X board says: “I am delighted to welcome Werner to the arGEN-X supervisory board. His experience in building successful life sciences companies, and impressive business and corporate development track record will prove highly instrumental in the Company’s move to the next level of success.”
Related Content

Evotec and Bayer announce new kidney disease study
Evotec and Bayer have announced the initiation of a phase 2 clinical study in kidney …

Evotec shares progress in Bristol Myers Squibb neuroscience collaboration
Evotec has announced that it has reached important scientific progress within the neuroscience collaboration with …

Evotec and Dewpoint Therapeutics enter strategic partnership
Evotec and Dewpoint Therapeutics have announced a strategic R&D collaboration for the advancement of Dewpoint’s …






